Las Vegas, NV, United States
Las Vegas, NV, United States

Time filter

Source Type

News Article | May 5, 2017
Site: www.businesswire.com

CHANDLER, Ariz.--(BUSINESS WIRE)--At 11:01 p.m. on Thursday, May 4, 2017, the Arizona Senate passed HB 2547: university infrastructure capital financing; appropriations, paving the way for up to $1 billion in bonds to expand and maintain university research infrastructure at Arizona’s public universities. HB2547 is part of a set of budget bills that make up Arizona’s $9.8 billion budget for the fiscal year the begins on July 1, 2017. The bill’s primary sponsor was Representative Paul Boyer (LD-20). Representative Boyer is the Chairman of the House Education Committee, and is a member of the House Health and County and Municipal Affairs Committees. A vehicle supporting the $1 billion investment in Arizona’s University Research Infrastructure was originally proposed in Arizona Governor Doug Ducey’s Executive Budget on January 13, 2017. The Governor’s Plan proposed allowing Arizona’s three state universities to apply the Transaction Privilege Tax (TPT) revenue that they create to support up to $1 billion in bonding for research and development, and deferred maintenance construction projects. While support for investing in Arizona’s future by expanding our university research infrastructure was strong in the community and with members of the legislature, concerns over the use of TPT revenue and the impact that it could have on other stakeholders was a legislative concern. Achieving the goal of an $1 billion investment would require creativity, collaboration and compromise. Reaching the Destination with a Different Vehicle Following months of committee hearings, discussions, stakeholder meetings and communication with constituents, a new funding plan was developed that combines a percentage of the new licensure and royalty agreements that are the result of research at Arizona’s public universities, with state funding support and a university match to allow for up to $1 billion in bonding capacity for Arizona’s public universities. This plan became HB2547, which first passed in the Arizona House of Representatives (33-26), followed by the Arizona Senate (23-7), paves the way for a $1 billion investment in Arizona’s public universities and is on the way to the Governor’s desk. To view the full summary of HB 2547, visit http://www.azleg.gov/legtext/53leg/1R/summary/H.HB2547_05-04-17_HOUSEENGROSSED.DOCX.htm. In 2003, the Arizona Legislature authorized an annual appropriation of $35 million to construct roughly $500 million worth of university research facilities that was championed by then-Speaker Pro Tempore Bob Robson. These projects included the Biodesign Institute at Arizona State University, The University of Arizona’s Keating Bioresearch Building, which houses the UA BIO5 Institute, and Arizona Biomedical Collaborative 1 on the Phoenix Biomedical Campus. At Northern Arizona University, the Applied Research and Development facility has enabled the university to expand its research in the areas of national defense and infectious disease. Since the state’s investment in 2003, research activity conducted at Arizona’s public universities has increased 77 percent and now totals nearly $1.1 billion each year. University invention disclosures have increased 154 percent. Degrees awarded in high-demand fields, including key STEM (Science, Technology, Engineering and Math) fields, have increased 40 percent in the past six years alone. In fiscal 2015, Arizona’s three public universities were responsible for an estimated 102,000 jobs and $11 billion in total economic impact. “Our investments in university research infrastructure have been and will be a major economic driver,” shared Joan Koerber-Walker, president & CEO of the Arizona Bioindustry Association (AZBio). “Yet, measuring this impact in a purely economic sense overlooks the greater value that life science research represents. The greatest value comes from the life-saving and life-changing innovations that will make life better for people in Arizona and around the world. Arizona university researchers and their industry partners are discovering, developing, and delivering products and services that will help people stay healthy, aid them when they are ill and improve their quality of life. By doubling down on our earlier research infrastructure investments, Arizona’s leaders are paving the way to a brighter future for the people of Arizona. We are truly grateful to Governor Doug Ducey and the Arizona Legislature for their vision and their commitment to invest in Arizona’s future.” “Arizona has passed a budget that prioritizes education, boosts teacher pay and invests in our universities — all without raising taxes on hardworking Arizonans,” said Governor Ducey. “For the first time in a decade, we are making significant and lasting investments to grow our state — in state parks, in public schools and universities, in our roads and highways, and in programs to combat drug addiction, provide second chances to inmates and place foster children in permanent homes. This would not be possible without the hard work to balance our budget over recent years. And it should come as no surprise that we are investing where it can really make a difference. I thank the legislature for their hard work and look forward to building on these gains to continue expanding opportunity for all Arizonans.” About the Arizona Bioindustry Association, Inc. (AZBio) A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.


Lekkerkerker-Teunissen K.,Dunea | Lekkerkerker-Teunissen K.,Technical University of Delft | Benotti M.J.,Applied Research and Development | Benotti M.J.,Batelle Memorial Institute | And 3 more authors.
Separation and Purification Technology | Year: 2012

Differences in the degradation and transformation of atrazine (ATZ), carbamazepine (CBZ), diclofenac (DCF), and sulfamethoxazole (SMX) in deionized water during UV and UV/H2O2 treatment using lowpressure (LP) and medium pressure (MP) UV lamps, were assessed using a collimated beam apparatus. UV doses ranged from 300700 mJ/cm2 and H 2O 2 doses ranged from 010 mg/L. Liquid chromatography with tandem mass spectrometry (LC-MS/MS) was used to measure concentrations of the parent compounds and quadrupole time-of-flight mass spectrometry (QToF-MS) was used to screen for transformation products following treatment. In general, there was little difference in compound degradation and transformation between LP and MP UV lamps in both UV and UV/H 2O 2 treatments. Removal of ATZ, SMX and DCF was largely attributed to direct photodegradation whereas CBZ was not appreciably removed by UV or UV/H 2O 2 treatment. All four compounds yielded transformation products following UV or UV/H 2O 2 treatment with LP and MP lamps. Transformation pathways were determined using accurate mass estimation to determine elemental composition, and relative abundance was determined using ion counts. For ATZ and CBZ, the transformation pathway was non-sequential, whereas for DCF and SMX, the transformation pathway was sequential. The approach outlined in this paper can be used to assess unknown transformation products formed during oxidation of organic micropollutants during water treatment. © 2012 Elsevier B.V. All rights reserved.


Lekkerkerker-Teunissen K.,Technical University of Delft | Benotti M.J.,Batelle Memorial Institute | Snyder S.A.,Applied Research and Development | van Dijk H.C.,Technical University of Delft
Separation and Purification Technology | Year: 2012

Differences in the degradation and transformation of atrazine (ATZ), carbamazepine (CBZ), diclofenac (DCF), and sulfamethoxazole (SMX) in deionized water during UV and UV/H 2O 2 treatment using low-pressure (LP) and medium pressure (MP) UV lamps, were assessed using a collimated beam apparatus. UV doses ranged from 300-700mJ/cm 2 and H 2O 2 doses ranged from 0-10mg/L. Liquid chromatography with tandem mass spectrometry (LC-MS/MS) was used to measure concentrations of the parent compounds and quadrupole time-of-flight mass spectrometry (QToF-MS) was used to screen for transformation products following treatment. In general, there was little difference in compound degradation and transformation between LP and MP UV lamps in both UV and UV/H 2O 2 treatments. Removal of ATZ, SMX and DCF was largely attributed to direct photodegradation whereas CBZ was not appreciably removed by UV or UV/H 2O 2 treatment. All four compounds yielded transformation products following UV or UV/H 2O 2 treatment with LP and MP lamps. Transformation pathways were determined using accurate mass estimation to determine elemental composition, and relative abundance was determined using ion counts. For ATZ and CBZ, the transformation pathway was non-sequential, whereas for DCF and SMX, the transformation pathway was sequential. The approach outlined in this paper can be used to assess unknown transformation products formed during oxidation of organic micropollutants during water treatment. © 2012 Elsevier B.V.

Loading Applied Research and Development collaborators
Loading Applied Research and Development collaborators